Bioanalytical Testing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Bioanalytical Testing Services Market is projected to grow from USD 5.01 Billion in 2025 to USD 6.83 Billion by 2031, expanding at a CAGR of 5.31%. These services, which involve the quantitative measurement of drugs, metabolites, and biomarkers in biological systems, are essential for supporting pharmacokinetics and toxicokinetics studies throughout drug development. The market is primarily driven by rising pharmaceutical research expenditures and the need to develop complex biologics and biosimilars that require rigorous safety validation. According to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested approximately €55.00 billion in R&D in Europe during 2024, a significant financial commitment that underpins the increasing demand for outsourced testing to ensure regulatory compliance for expanding drug pipelines.

However, this market expansion faces significant challenges due to a shortage of skilled professionals capable of executing advanced analytical methodologies. The complexity of assays required for large molecules necessitates specialized expertise in techniques such as mass spectrometry and ligand binding. A scarcity of qualified personnel leads to operational bottlenecks and delays in project timelines, limiting the ability of service providers to fully capitalize on the growing volume of research activities.

Market Drivers

The rapid expansion of biologics and biosimilars development pipelines significantly reinforces the demand for specialized bioanalytical testing services. As pharmaceutical companies increasingly prioritize large molecule therapeutics over traditional small molecules, there is a substantial rise in the requirement for intricate immunogenicity testing and pharmacokinetic assays. This transition necessitates analytical platforms capable of characterizing complex protein structures and ensuring safety profiles meet rigorous standards for approval. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' report released in January 2024, the agency approved 55 novel therapeutics, a figure that underscores the accelerating pace of drug innovation and the consequential need for comprehensive laboratory validation to support these diverse pipelines.

Concurrently, the surge in global clinical trial volume and complexity acts as a critical driver for bioanalytical service adoption. Modern clinical studies increasingly involve multi-regional sites and stratified patient populations, requiring harmonized testing protocols to efficiently process vast quantities of biological samples. This escalating operational burden compels sponsors to rely on external partners for high-throughput bioanalysis to maintain study integrity. According to the National Library of Medicine's 'Trends, Charts, and Maps' update in May 2024, the cumulative number of registered clinical studies on ClinicalTrials.gov reached 492,996, highlighting the immense scale of research activities requiring support. Furthermore, the financial magnitude of this outsourcing trend is evident in the performance of major service providers; Icon PLC, for instance, reported a full-year revenue of $8.12 billion in February 2024, reflecting the industry-wide reliance on contract research organizations to manage these intensive testing requirements.

Market Challenges

The scarcity of qualified personnel poses a substantial barrier to the growth of the global bioanalytical testing services market. As pharmaceutical development shifts toward complex biologics and biosimilars, the demand for advanced analytical testing has surged. However, the sophisticated assays required for these molecules demand technicians with specialized expertise in intricate methodologies like mass spectrometry and ligand binding. When service providers lack a workforce with these specific competencies, they struggle to process sample volumes efficiently, creating operational bottlenecks that extend project turnaround times and compromise the ability of contract research organizations to meet rigorous regulatory timelines.

This workforce constraint directly impedes the market’s capacity to absorb the rising volume of outsourced research. Without adequate staffing, testing facilities cannot scale operations to match the pace of drug discovery, forcing them to delay study initiations or decline new contracts. According to the Association of the British Pharmaceutical Industry and the BioIndustry Association, the life sciences sector faces a critical pressure point in 2025, where an additional 70,000 jobs will be required by 2035 to meet industry demand. This projected shortfall highlights a widening skills gap that restricts service providers from fully leveraging available capital investments, thereby slowing the overall trajectory of market expansion.

Market Trends

The Global Bioanalytical Testing Services Market is currently experiencing a surge in cell and gene therapy analytical services, driven by the unique technical requirements of these advanced modalities which differ fundamentally from standard biologics. Unlike monoclonal antibodies, cell and gene therapies require specialized testing for viral vector characterization, transduction efficiency, and long-term genomic stability, compelling service providers to invest in dedicated, high-containment testing infrastructures. The maturation and financial resilience of this sector are accelerating these specialized service needs; according to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, investment in the cell and gene therapy sector rose by 30 percent, a significant capital influx that directly fuels the demand for intricate bioanalytical validation to support expanding development pipelines.

Concurrently, the market is defined by the expansion of biomarker and companion diagnostic testing as pharmaceutical strategies increasingly pivot toward precision medicine and patient stratification. This trend forces bioanalytical laboratories to evolve beyond traditional pharmacokinetic assays, requiring the integration of high-sensitivity platforms for biomarker validation and the co-development of diagnostic assays that run parallel to clinical studies. The operational growth resulting from this shift is evident in the performance of major industry players; according to Labcorp's 'Annual Report for Fiscal Year Ending 12/31, 2024' released in February 2025, the company's Biopharma Laboratory Services segment, which encompasses central laboratory and biomarker capabilities, achieved a revenue of $2.92 billion, representing a 5.3 percent increase driven by organic demand for these complex analytical services.

Key Players Profiled in the Bioanalytical Testing Services Market

• Thermo Fisher Scientific, Inc.
• ICON PLC
• Charles River Laboratories International, Inc.
• Covance, Inc. (Labcorp Drug Development)
• IQVIA Inc.
• Syneos Health Inc.
• SGS S.A.
• Intertek Group PLC
• Pace Analytical Services, LLC

Report Scope

In this report, the Global Bioanalytical Testing Services Market has been segmented into the following categories:

Bioanalytical Testing Services Market, by Type:

• Cell-based Assays
• Bacterial cell-based assays
• Viral cell-based assays
• Virology Testing
• In Vitro Virology Testing
• In Vivo Virology Testing
• Species-specific Viral PCR Assays Method Development
• Optimization and Validation
• Serology
• Immunogenicity and Neutralizing Antibodies
• Biomarker Testing
• Pharmacokinetic Testing
• Other Services

Bioanalytical Testing Services Market, by Application:

• Oncology
• Neurology
• Infectious Diseases
• Gastroenterology
• Cardiology
• Other Applications

Bioanalytical Testing Services Market, by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Contract Development and Manufacturing Organizations
• Contract Research Organizations

Bioanalytical Testing Services Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioanalytical Testing Services Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.